Zobrazeno 1 - 10
of 89
pro vyhledávání: '"M, Vadiaka"'
Autor:
Skopelitis H, N. Tsavaris, E. Tzima, E. Pagouni, Petros Kopterides, D. Karadima, D. Loukeris, G. Kolliokosta, V. Xyla, Christos Koufos, M. Vadiaka, C. Kosmas, E. Batziou, N. Kosmas
Publikováno v:
European Journal of Cancer Care. 17:167-173
Even though significant progress has been made, chemotherapy-induced emesis remains a challenging problem. Few studies focus on emesis in patients treated with carboplatin and the observation period is limited to the initial 24 h following chemothera
Autor:
A. Dimitrakopoulos, George Papastratis, T. Giannakakis, N. Tsavaris, H. Tsipras, H. Margaris, M. Vadiaka, Panagiotis Gouveris, Efstathios Papalambros, D. Karadima, C. Kosmas, Sofia Rokana, Aristidis Polyzos, N. Ziras
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:514-519
To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy.Irinotecan was randomly administe
Autor:
H. Tsipras, H. Margaris, A. Dimitrakopoulos, C. Kosmas, Nicolas Tsavaris, M. Vadiaka, Efstathios Papalambros, K. Gennatas, A. Macheras, George Papastratis, Athanasios Giannopoulos, Ch. Koufos, Aristidis Polyzos
Publikováno v:
Chemotherapy. 48:94-99
The purpose of the present study was to investigate the association between performance status (PS) and mean dose of irinotecan (CPT-11) in patients with recurrent advanced colorectal cancer relapsing after 5-fluorouracil and leucovorin chemotherapy.
Autor:
D. Pikazis, G. Vaiopoulos, C. Kosmas, N. Sakellaropoulos, G. Karargyris, M. Vadiaka, N. Tsavaris
Publikováno v:
Journal of Chemotherapy. 14:102-105
The relationship between polymyositis and malignancy is well known. Several types of tumors can be complicated with myositis and/or more frequently dermatomyositis. It has been suggested that tumors of the large bowel are rarely complicated by myosit
Autor:
Nikolaos V. Sipsas, Elias Skopelitis, Nikolaos Tsavaris, A. Karabelis, M. Vadiaka, Panayiotis D. Ziakas, Theodore Kordossis, Christos Kosmas
Publikováno v:
Scandinavian journal of infectious diseases. 39(9)
The objective of this investigation was to assess retrospectively the safety and the efficacy of oral ciprofloxacin plus cefuroxime axetil compared to the combination of oral ciprofloxacin plus amoxicillin/clavulanate, as initial outpatient treatment
Autor:
N, Tsavaris, C, Kosmas, M, Vadiaka, E, Skopelitis, P, Kopteridis, S, Pamouki, M, Efremidis, H, Kasparian, I, Moisakis, D, Sakelariou, C, Koufos
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 10(2)
Cardiotoxicity associated with 5-fluorouracil (5FU) administration is infrequently reported in the literature, albeit case reports of acute coronary syndromes have been published. In the present study, patients undergoing 5FU chemotherapy were tested
Autor:
G. Papastratis, E. Skopelitis, C. Kosmas, George C. Zografos, K. Gennatas, E. Margaris, Sofia Rokana, M. Vadiaka, Gregory Kouraklis, N. Tsavaris, V. Xila
Publikováno v:
Journal of chemotherapy (Florence, Italy). 14(4)
In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer
Publikováno v:
Medical oncology (Northwood, London, England). 18(3)
A 37-yr-old man who had undergone renal transplantation for end-stage renal failure presented with a large right pelvic mass obstructing the transplanted kidney. Initially, this was diagnosed as an anaplastic tumor while he had been on immunosuppress
Autor:
A. Agelopoulou, D. Boulamatsis, A. Kontos, N. Tsavaris, C. Kosmas, Christos Koufos, Stavros Sougioultzis, M. Vadiaka
Publikováno v:
Journal of chemotherapy (Florence, Italy). 13(6)
We studied tropisetron (T) in patients with breast cancer receiving standard adjuvant chemotherapy with CEF (cyclophosphamide, epirubicin and 5-fluorouracil) over 3 consecutive cycles; T was administered alone or in combination with dexamethasone (D)
Autor:
Kostadinos Fotiadis, M. Vadiaka, Panagiotis Vachiotis, Nicolas Tsavaris, Sofia Rokana, Kostadinos Genatas, Christos Kosmas, A. Dimitrakopoulos, Aristidis Polyzos, G Karatzas, Platon Paliaros
Publikováno v:
Tumori. 87(5)
Dipyridamole, an inhibitor of nucleoside transport, increases the activity of 5-fluorouracil in a dose-dependent manner. The purpose of the present study was to determine whether dipyridamole with 5-fluorouracil and leucovorin gave an improved therap